DYNE THERAPEUTICS INC

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

04 Jan 2024 19:46:36 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

03 Jan 2024 13:25:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

03 Jan 2024 03:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02 Jan 2024 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at November Investor Conferences

07 Nov 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

30 Oct 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at October Investor Conferences

28 Sep 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

20 Sep 2023 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 Sep 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

03 Aug 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Healthcare Conference

01 Jun 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

25 May 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

17 May 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

11 May 2023 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

03 May 2023 04:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

02 May 2023 13:46:03 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

23 Mar 2023 04:30:17 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

20 Mar 2023 04:30:24 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 Mar 2023 04:30:00 By Nasdaq GlobeNewswire